Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Is an antioxidative capacity of HI-6 oxime a key factor to improve the therapy with irinotecan? (CROSBI ID 544520)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Suzana Berend, Ana Lucić Vrdoljak, Božica Radić, Jasenka Piljac-Žegarac, Marin Mladinić, Davor Želježić, Nevenka Kopjar Is an antioxidative capacity of HI-6 oxime a key factor to improve the therapy with irinotecan? // Toxicology letters / Tsatsakis, Aristidis M., Liesivuori, Jyrki (ur.). 2008. str. S151-x

Podaci o odgovornosti

Suzana Berend, Ana Lucić Vrdoljak, Božica Radić, Jasenka Piljac-Žegarac, Marin Mladinić, Davor Želježić, Nevenka Kopjar

engleski

Is an antioxidative capacity of HI-6 oxime a key factor to improve the therapy with irinotecan?

New and improved therapy modalities currently employed in the management of malignant diseases significantly contribute to the overall survival rate in cancer patients. Therefore, some compounds although not primarily designed as supportive drugs in chemotherapy, are promising candidates for possible clinical use. Our in vitro and in vivo experiments have demonstrated that HI-6 could “ protect” cholinesterases against the irinotecan, one of frequently used antineoplastic drugs, and in that way a part of cholinergic symptoms might be reduced. Interestingly, certain antioxidants may counteract the effects of chemotherapy-induced oxidative stress on the cell cycle and enhance the cytotoxicity of antineoplastic agents. So with the purpose to investigate the levels of oxidative stress and DNA damage (lipid peroxidation, the alkaline comet assay and micronucleus assay) related to treatments with irinotecan and HI-6 given alone or in combination we also focused on the assessment of possible antioxidative capacity of HI-6. In view of the DPPH assay results, HI-6 shows moderate radical scavenging at the tested concentration. Administration of HI-6 alone or with irinotecan diminished the levels of TBARS in rat plasma. Confirmatory results regarding HI-6 efficacy were also obtained by the alkaline comet and micronucleus assay. When given alone, it mostly did not induce significant disturbances in the level of primary DNA damage in somatic cells of treated rats and did not significantly induce the formation of micronuclei. Results obtained in the present study seems to be a proper argument to consider HI-6 as beneficial substance during chemotherapy.

HI-6; irinotecan; antioxidative capacity

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

S151-x.

2008.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Toxicology letters

Tsatsakis, Aristidis M., Liesivuori, Jyrki

0378-4274

Podaci o skupu

45th Congress of the European Societies of Toxicology

poster

05.10.2008-08.10.2008

Rodos, Grčka

Povezanost rada

Temeljne medicinske znanosti

Indeksiranost